Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivegacetor - Roche

Next Previous
Drug Profile

Nivegacetor - Roche

Alternative Names: RG-6289

Latest Information Update: 07 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antidementias; Azabicyclo compounds; Bridged bicyclo compounds; Ethers; Fluorobenzenes; Methyl ethers; Pyridazines; Pyrrolidines; Triazoles
  • Mechanism of Action Amyloid precursor protein secretase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease

Most Recent Events

  • 08 Jul 2026 Phase-II/III clinical trials in Alzheimer's disease (Prevention, Combination therapy) in Colombia (PO) (NCT06996730)
  • 08 Jul 2026 Phase-II/III clinical trials in Alzheimer's disease (Prevention, Monotherapy) in Colombia (PO) (NCT06996730)
  • 03 Dec 2025 Efficacy data from a phase II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top